- Tipos de Cáncer
Tipos de Cáncer
Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.A a la Z - Tratamiento
Tratamiento del Cáncer
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
- Riesgo de concer y prevencion
- Drogas de Cáncer
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
- Lidiando
Lidiando con el Cáncer
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
- Profesionales de la salud
- Estudios Clínicos
Notas para enfermeros 
¿Cuál es mi riesgo? k? 
OncoPilot: Manejando su experiencia del cáncer 
OncoLink Cancer Blogs
Community Events Calendar 
Abramson Cancer Center 
NCI CANCERLIT® Search: Hairy Cell Leukemia - September 2002
National Cancer Institute®
Ultima Vez Modificado: 1 de septiembre del 2002
- Epithelioid microgranulomas after Pentostatin therapy in hairy cell leukaemia.
- Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia.
- Reactive polyclonal T-cell lymphocytosis mimicking Sezary syndrome in a patient with hairy cell leukemia.
Table of Contents
1
UI - 12010371
AU - Sironi M; Lodato A; Sciariada L; Spinelli M
TI -
Epithelioid microgranulomas after Pentostatin therapy in hairy cell
leukaemia.
SO - Histopathology 2002 May;40(5):483-5
2
UI - 11602410
AU - Lauria F; Lenoci M; Annino L; Raspadori D; Marotta G; Bocchia M; Forconi
TI -
F; Gentili S; La Manda M; Marconcini S; Tozzi M; Baldini L; Zinzani PL;
Foa R
Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with
progressed hairy cell leukemia.
SO - Haematologica 2001 Oct;86(10):1046-50
AD - Department of Hematology "A. Sclavo" Hospital, via Tufi 1, 53100 Siena,
Italy. lauria@unisi.it
BACKGROUND AND OBJECTIVES: Recently, a chimeric monoclonal antibody
(MoAb) directed against the CD20 antigen (rituximab) has been
successfully introduced in the treatment of several CD20-positive B-cell
neoplasias and particularly of follicular lymphomas. Based on these
premises we evaluated the efficacy and the toxicity of chimeric
anti-CD20 monoclonal antibody (MoAb) in relapsed/progressed hairy cell
leukemia (HCL). DESIGN AND METHODS: Ten patients with
relapsed/progressed HCL entered the study. Eight patients were males and
two females with a median age of 55 years (range 41-78) and all of them
had been previously treated with 2-chlorodeoxyadenosine and/or
deoxycoformycin and a-interferon. Two out of 10 patients were anemic (Hb
< 10 g/dL), 4 thrombocytopenic (Plt < 100 x 10(9)/L), 3 had fewer than
1.0 x 10(9)/L neutrophils and 3 had circulating hairy cells (HC). All
patients received 375 mg/m2 i.v. of anti-CD20 MoAb once a week for 4
doses. RESULTS: All patients were evaluable for response, one patient
showing a complete remission and 4 a partial response. Adverse
reactions, such as fever, chills, bone pain, hypotension and
thrombocytopenia, were transient and mild (grade 1-2) and occurred only
during the first course of treatment. One month after the last infusion,
patients who had had anemia, neutropenia or thrombocytopenia, recovered
normal peripheral blood values. Circulating HC also disappeared within
one month. Immunostained bone marrow biopsies were checked 1, 3 and 6
months after the end of therapy and in 5 out of 10 patients a >50%
reduction of bone marrow HC infiltration was recorded. INTERPRETATION
AND CONCLUSIONS: On the basis of these preliminary results observed in
10 patients with progressed HCL, it appears that treatment with
anti-CD20 MoAb is safe and effective in at least 50% of patients,
particularly in those with a less evident bone marrow infiltration (50%)
and in those previously splenectomized.
3
UI - 11602434
AU - Wulf GG; Schulz H; Hallermann C; Kunze E; Wormann B
TI -
Reactive polyclonal T-cell lymphocytosis mimicking Sezary syndrome in a
patient with hairy cell leukemia.
SO - Haematologica 2001 Oct;86(10):E27
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
